Study Title and Description
Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature.
Key Questions Addressed
|8||Key Question 8 - Case studies/series and potential harms of nonstandard interventions for CDI|
Primary Publication Information
|Title||Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature.|
|Author||Abougergi MS., Broor A., Cui W., Jaar BG.|
|Country||Department of Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland 21224, USA. firstname.lastname@example.org|
Pubmed ID: 20063275
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Question 4 - Case studies/series and potential harms of nonstandard interventions for CDI (Table C11)
|Question... Follow Up||Answer||Follow-up Answer|
|Subject/Study Details||21 patients with C. difficile colitis defined as C. difficile cytotoxin positive feces + diarrhea + other symptoms of abdominal pain and/or distention or fever +a leukoid reaction (white blood count of 20,000 cell/mm3 or more) + radiographic evidence of colitis or pseudomembranes by colonoscopy or sigmoidoscopy 13 females and 8 males; age = 68 years (13) (mean [SD]) All patients were seriously ill with sepsis and other comorbidities Retrospective chart review|
|Interventions||intravenous intramuscularmunoglobulin (IVIG) as an adjuvant treatment to standard antibiotics Dose: mode of 250 mg/kg for 1-3 days (dose range = 200- 1,250 mg/kg)|
|Clinical Diarrhea Outcomes||9 patients (43%) survived with resolution of clinical symptoms of C. difficile colitis|
|Adverse Effects (AE) Harms||Pulmonary edema in 1 patient|
Results & Comparisons
No Results found.